AAP
RCEL icon

Arax Advisory Partners’s Avita Medical RCEL Stock Holding History

Arax Advisory Partners’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.5K Buy
7,153
+7,123
+23,743% +$30.7K ﹤0.01% 3686
2026
Q1 		$111 Buy
30
+20
+200% +$84 ﹤0.01% 3604
2025
Q4 		$35 Sell
10
-431
-98% -$1.72K ﹤0.01% 3976
2025
Q3 		$2.25K Buy
+441
New +$2.3K ﹤0.01% 3090

Other funds holding RCEL

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Arax Advisory Partners's RCEL Position: Q2 2026 in Review

Arax Advisory Partners increased its Avita Medical (RCEL) stake by 23,743% in Q2 2026, buying an estimated $30.7K and bringing the position to 7,153 shares worth $29.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3686.

Arax Advisory Partners first reported a position in RCEL in Q3 2025 and has held it in 4 quarters since. 73 funds tracked by Wall St. Rank hold RCEL as of Q2 2026.

  • Arax Advisory Partners held 7,153 shares of Avita Medical worth $29.5K as of Q2 2026.
  • Arax Advisory Partners bought 7,123 Avita Medical shares in Q2 2026, an estimated $30.7K.
  • Avita Medical made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3686 holding.
  • Arax Advisory Partners first reported a position in Avita Medical in Q3 2025 and has held it in 4 quarters since.
  • 73 funds tracked by Wall St. Rank held Avita Medical as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.